KRYS
Price
$201.21
Change
-$1.82 (-0.90%)
Updated
Nov 13 closing price
Capitalization
5.82B
108 days until earnings call
Intraday BUY SELL Signals
ZLDPF
Price
$80.50
Change
+$1.78 (+2.26%)
Updated
Nov 13 closing price
Capitalization
5.4B
Intraday BUY SELL Signals
Interact to see
Advertisement

KRYS vs ZLDPF

Header iconKRYS vs ZLDPF Comparison
Open Charts KRYS vs ZLDPFBanner chart's image
Krystal Biotech
Price$201.21
Change-$1.82 (-0.90%)
Volume$199.5K
Capitalization5.82B
Zealand Pharma A/S
Price$80.50
Change+$1.78 (+2.26%)
Volume$500
Capitalization5.4B
KRYS vs ZLDPF Comparison Chart in %
View a ticker or compare two or three
VS
KRYS vs. ZLDPF commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a Buy and ZLDPF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (KRYS: $201.21 vs. ZLDPF: $80.50)
Brand notoriety: KRYS and ZLDPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 58% vs. ZLDPF: 150%
Market capitalization -- KRYS: $5.82B vs. ZLDPF: $5.4B
KRYS [@Biotechnology] is valued at $5.82B. ZLDPF’s [@Biotechnology] market capitalization is $5.4B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 1 FA rating(s) are green whileZLDPF’s FA Score has 2 green FA rating(s).

  • KRYS’s FA Score: 1 green, 4 red.
  • ZLDPF’s FA Score: 2 green, 3 red.
According to our system of comparison, ZLDPF is a better buy in the long-term than KRYS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 4 TA indicator(s) are bullish while ZLDPF’s TA Score has 7 bullish TA indicator(s).

  • KRYS’s TA Score: 4 bullish, 5 bearish.
  • ZLDPF’s TA Score: 7 bullish, 4 bearish.
According to our system of comparison, ZLDPF is a better buy in the short-term than KRYS.

Price Growth

KRYS (@Biotechnology) experienced а +0.62% price change this week, while ZLDPF (@Biotechnology) price change was +21.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.47%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +62.00%.

Reported Earning Dates

KRYS is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (+1.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($5.82B) has a higher market cap than ZLDPF($5.4B). KRYS has higher P/E ratio than ZLDPF: KRYS (30.17) vs ZLDPF (5.68). KRYS YTD gains are higher at: 29.599 vs. ZLDPF (-23.095). ZLDPF has higher annual earnings (EBITDA): 7.27B vs. KRYS (158M). ZLDPF has more cash in the bank: 16.6B vs. KRYS (682M). KRYS has less debt than ZLDPF: KRYS (9.68M) vs ZLDPF (397M). ZLDPF has higher revenues than KRYS: ZLDPF (9.11B) vs KRYS (359M).
KRYSZLDPFKRYS / ZLDPF
Capitalization5.82B5.4B108%
EBITDA158M7.27B2%
Gain YTD29.599-23.095-128%
P/E Ratio30.175.68531%
Revenue359M9.11B4%
Total Cash682M16.6B4%
Total Debt9.68M397M2%
FUNDAMENTALS RATINGS
KRYS vs ZLDPF: Fundamental Ratings
KRYS
ZLDPF
OUTLOOK RATING
1..100
2286
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
46
Fair valued
PROFIT vs RISK RATING
1..100
2871
SMR RATING
1..100
5319
PRICE GROWTH RATING
1..100
4050
P/E GROWTH RATING
1..100
9813
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZLDPF's Valuation (46) in the null industry is in the same range as KRYS (76) in the Pharmaceuticals Major industry. This means that ZLDPF’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (28) in the Pharmaceuticals Major industry is somewhat better than the same rating for ZLDPF (71) in the null industry. This means that KRYS’s stock grew somewhat faster than ZLDPF’s over the last 12 months.

ZLDPF's SMR Rating (19) in the null industry is somewhat better than the same rating for KRYS (53) in the Pharmaceuticals Major industry. This means that ZLDPF’s stock grew somewhat faster than KRYS’s over the last 12 months.

KRYS's Price Growth Rating (40) in the Pharmaceuticals Major industry is in the same range as ZLDPF (50) in the null industry. This means that KRYS’s stock grew similarly to ZLDPF’s over the last 12 months.

ZLDPF's P/E Growth Rating (13) in the null industry is significantly better than the same rating for KRYS (98) in the Pharmaceuticals Major industry. This means that ZLDPF’s stock grew significantly faster than KRYS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSZLDPF
RSI
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
55%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
76%
Bullish Trend 3 days ago
72%
Momentum
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
68%
MACD
ODDS (%)
Bearish Trend 3 days ago
79%
Bullish Trend 3 days ago
66%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
57%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
61%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
74%
Declines
ODDS (%)
Bearish Trend 24 days ago
74%
Bearish Trend 9 days ago
55%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
74%
Bullish Trend 3 days ago
73%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
36%
View a ticker or compare two or three
Interact to see
Advertisement
KRYS
Daily Signal:
Gain/Loss:
ZLDPF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FBCIX80.760.41
+0.51%
American Funds Capital Income Bldr 529F2
PIIJX16.760.06
+0.36%
Principal Diversified Intl J
PCBKX12.910.03
+0.23%
Victory Pioneer Balanced R6
LONGX15.020.02
+0.13%
Longboard I
ASVIX9.74N/A
N/A
American Century Small Cap Value Inv

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with ACLX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
+0.01%
ACLX - KRYS
50%
Loosely correlated
-0.09%
VRDN - KRYS
49%
Loosely correlated
+1.79%
IDYA - KRYS
49%
Loosely correlated
-0.19%
CGON - KRYS
48%
Loosely correlated
+1.47%
NUVL - KRYS
47%
Loosely correlated
+0.91%
More

ZLDPF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZLDPF has been loosely correlated with KRYS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLDPF jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZLDPF
1D Price
Change %
ZLDPF100%
+7.42%
KRYS - ZLDPF
46%
Loosely correlated
+0.01%
CLDX - ZLDPF
30%
Poorly correlated
-0.49%
NERV - ZLDPF
22%
Poorly correlated
+0.76%
SNDX - ZLDPF
22%
Poorly correlated
-5.30%
MIST - ZLDPF
22%
Poorly correlated
+1.05%
More